Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial. / Kirkedal, Ann Britt Kiholm; Møller, Julie Elkjær; Stensballe, Lone Graff; Zoffmann, Vibeke.

I: Vaccines, Bind 11, Nr. 1, 67, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kirkedal, ABK, Møller, JE, Stensballe, LG & Zoffmann, V 2023, 'Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial', Vaccines, bind 11, nr. 1, 67. https://doi.org/10.3390/vaccines11010067

APA

Kirkedal, A. B. K., Møller, J. E., Stensballe, L. G., & Zoffmann, V. (2023). Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial. Vaccines, 11(1), [67]. https://doi.org/10.3390/vaccines11010067

Vancouver

Kirkedal ABK, Møller JE, Stensballe LG, Zoffmann V. Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial. Vaccines. 2023;11(1). 67. https://doi.org/10.3390/vaccines11010067

Author

Kirkedal, Ann Britt Kiholm ; Møller, Julie Elkjær ; Stensballe, Lone Graff ; Zoffmann, Vibeke. / Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial. I: Vaccines. 2023 ; Bind 11, Nr. 1.

Bibtex

@article{5ce33c24af804886871fa0b90b547b20,
title = "Parents{\textquoteright} and Health Professionals{\textquoteright} Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial",
abstract = "Declining levels and duration of passively acquired maternal antibodies prompted a Danish trial to test the feasibility of advancing administration of the first measles, mumps, and rubella vaccine (MMR1) from 15 to 6 months of age. A trial-embedded qualitative study aimed to understand parents{\textquoteright} (N = 24) and health professionals{\textquoteright} (N = 11) attitudes about the measles, mumps, and rubella vaccine (MMR) in general and about advancing MMR1 administration. Overly positive parent attitudes were contrasted by members of a vaccine-skeptical organization including parents considering that their child was seriously vaccine-injured long ago. Parents{\textquoteright} attitudes to advancing MMR1 mirrored their attitudes about the MMR vaccine in general, with four positions along a continuum of trust in the healthcare system: unquestioning trust, acceptance after careful consideration, challenging indecisiveness, and defensive rejection. Low tolerance was identified between vaccine supporters and vaccine opponents. Parents of children with perceived serious vaccine-related injuries described lifelong unresolved feelings of guilt. Supporters of advanced MMR1 saw it as a timely and convenient administration of a well-known vaccine, whereas opponents feared it would disturb the children{\textquoteright}s immature immune systems and emphasized difficulties in recognizing side effects so early in life. Health professionals were supportive of advancing the MMR1 vaccine and they carefully challenged the parents. Current MMR vaccine supporters show readiness to advance MMR1 administration.",
keywords = "decision making, healthcare professionals, MMR vaccine, parental attitude, self-determined choices, trust, vaccine opponents, vaccine supporters",
author = "Kirkedal, {Ann Britt Kiholm} and M{\o}ller, {Julie Elkj{\ae}r} and Stensballe, {Lone Graff} and Vibeke Zoffmann",
note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2023",
doi = "10.3390/vaccines11010067",
language = "English",
volume = "11",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

RIS

TY - JOUR

T1 - Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial

AU - Kirkedal, Ann Britt Kiholm

AU - Møller, Julie Elkjær

AU - Stensballe, Lone Graff

AU - Zoffmann, Vibeke

N1 - Publisher Copyright: © 2022 by the authors.

PY - 2023

Y1 - 2023

N2 - Declining levels and duration of passively acquired maternal antibodies prompted a Danish trial to test the feasibility of advancing administration of the first measles, mumps, and rubella vaccine (MMR1) from 15 to 6 months of age. A trial-embedded qualitative study aimed to understand parents’ (N = 24) and health professionals’ (N = 11) attitudes about the measles, mumps, and rubella vaccine (MMR) in general and about advancing MMR1 administration. Overly positive parent attitudes were contrasted by members of a vaccine-skeptical organization including parents considering that their child was seriously vaccine-injured long ago. Parents’ attitudes to advancing MMR1 mirrored their attitudes about the MMR vaccine in general, with four positions along a continuum of trust in the healthcare system: unquestioning trust, acceptance after careful consideration, challenging indecisiveness, and defensive rejection. Low tolerance was identified between vaccine supporters and vaccine opponents. Parents of children with perceived serious vaccine-related injuries described lifelong unresolved feelings of guilt. Supporters of advanced MMR1 saw it as a timely and convenient administration of a well-known vaccine, whereas opponents feared it would disturb the children’s immature immune systems and emphasized difficulties in recognizing side effects so early in life. Health professionals were supportive of advancing the MMR1 vaccine and they carefully challenged the parents. Current MMR vaccine supporters show readiness to advance MMR1 administration.

AB - Declining levels and duration of passively acquired maternal antibodies prompted a Danish trial to test the feasibility of advancing administration of the first measles, mumps, and rubella vaccine (MMR1) from 15 to 6 months of age. A trial-embedded qualitative study aimed to understand parents’ (N = 24) and health professionals’ (N = 11) attitudes about the measles, mumps, and rubella vaccine (MMR) in general and about advancing MMR1 administration. Overly positive parent attitudes were contrasted by members of a vaccine-skeptical organization including parents considering that their child was seriously vaccine-injured long ago. Parents’ attitudes to advancing MMR1 mirrored their attitudes about the MMR vaccine in general, with four positions along a continuum of trust in the healthcare system: unquestioning trust, acceptance after careful consideration, challenging indecisiveness, and defensive rejection. Low tolerance was identified between vaccine supporters and vaccine opponents. Parents of children with perceived serious vaccine-related injuries described lifelong unresolved feelings of guilt. Supporters of advanced MMR1 saw it as a timely and convenient administration of a well-known vaccine, whereas opponents feared it would disturb the children’s immature immune systems and emphasized difficulties in recognizing side effects so early in life. Health professionals were supportive of advancing the MMR1 vaccine and they carefully challenged the parents. Current MMR vaccine supporters show readiness to advance MMR1 administration.

KW - decision making

KW - healthcare professionals

KW - MMR vaccine

KW - parental attitude

KW - self-determined choices

KW - trust

KW - vaccine opponents

KW - vaccine supporters

U2 - 10.3390/vaccines11010067

DO - 10.3390/vaccines11010067

M3 - Journal article

C2 - 36679912

AN - SCOPUS:85146774585

VL - 11

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

M1 - 67

ER -

ID: 336519371